Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over

  • Highly specialised technologies guidance
  • HST20
  • Published: 

Evidence

Documents containing the evidence that was used to develop the recommendations.

Supporting evidence